Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy

Neurology

Volumn 53, Issue 1, 1999, Pages 62-70

  Leppert, David ^a   Hughes, P ^c   Huber, S ^a   Erne, B ^a   Grygar, C ^a   Said, G ^b   Miller, K M ^c   Steck, A J ^a   Probst, A ^a   Fuhr, P ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b BICÊTRE HOSPITAL   (France)

^c University Hospitals Basel ^*

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; STROMELYSIN;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; BASEMENT MEMBRANE; CHRONIC DISEASE; CLINICAL ARTICLE; DEMYELINATING DISEASE; DEMYELINATION; DISEASE ACTIVITY; ELECTROPHYSIOLOGY; ENZYME INHIBITION; FEMALE; HUMAN; MALE; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; STROMA CELL; TISSUE INJURY; VASCULITIS;

EID: 0033551469     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.1.62     Document Type: Article

References (40)

1. Hartung H-P, Zielasek J, Jung S, Toyka KV. Effector mechanisms in demyelinating neuropathies. Rev Neurol 1996;152: 320-327.
2. Moore PM. Immune mechanisms in the primary and secondary vasculitides J Neurol Sci 1989;93:129-145.
3. Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996;19:474-487.
4. Dyck PJ, Benstead TJ, Conn DL, Stevens JC, Windernk AJ. Nonsystemic vasculitic neuropathy. Brain 1987;110:843-854.
5. Ben-Smith A, Gaston JSH, Barber PC, Winer JB. Isolation and characterisation of T lymphocytes from sural nerve biopsies on patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1996;61:362-368.
6. Matsumuro K, Izumo S, Umehara F, Osame M. Chronic inflammatory demyelinating polyneuropathy: histological and immunopathological studies on biopsied sural nerves. J Neurol Sci 1994;127:170-178.
7. Engelhardt A, Lörler H, Neundörfer B. Immunohistochemical findings in vasculitic neuropathies. Acta Neurol Scand 1993; 87:318-321.
8. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculopathy, without and with monoclonal gammopathy. Brain 1995;118:359-368.
9. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and responses to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-328.
10. Yong VW, Kreskoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998;21:75-80.
11. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SJ. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-4389.
12. Redford EJ, Smith KJ, Gregson NA, et al. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor alpha processing attenuates experimental autoimmune neuritis. Brain 1997;120:1895-1905.
13. Gijbels K, Galardy RE, Steinman L. Reversal of autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994;94:2177-2182.
14. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995;201:223-226.
15. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993;192:1175-1181.
16. Cuzner ML, Gveric D, Strand C, et al. The expression of tissue-type plasminogen-activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996;55:1194-1204.
17. Cossins JA, Clements JM, Ford J, et al. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 1997;94:590-598.
18. Anthony DC, Miller KM, Fearn S, et al. Matrix metalloproteinase expression in an experimentally induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol 1998;87:62-72.
19. Kieseier BC, Kiefer R, Clements JM, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998;121:159-166.
20. Clements JM, Cossins JA, Wells GMA, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor. J Neuroimmunol 1997;74:85-94.
21. Hughes PM, Wells GMA, Clements JM, et al. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 1998;121,481-494.
22. Kieseier BC, Clements JM, Pischel HB, et al. Matrix metalloproteinases MMP-9 and -7 are expressed in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol 1998;43:427-434.
23. Cornblath DR, Asbury AK, Albers JW. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-618.
24. Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990;33:1074-1087.
25. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-1077.
26. Uncini A, Di Muzio A, Sabatelli M, Magi S, Tonali P, Gambi D. Sensitivity and specificity of diagnostic criteria for conduction block in chronic inflammatory demyelinating polyneuropathy. Electroencephalogr Clin Neurophysiol 1993;89:161-169.
27. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol 1996;55:1181-1193.
28. Satoi H, Oka N, Kawasaki T, Miyamoto K, Akiguchi I, Kimura J. Mechanisms of tissue injury in vasculitic neuropathies. Neurology 1998;50:492-496.
29. Galis ZS, Kranzhöfer R, Fenton JW, Libby P. Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:483-489.
30. Ohkoshi N, Mizusawa H, Oguni E, Shoji S. Sural nerve biopsies in vasculitic neuropathies: morphometric analysis of the caliber of involved vessels. J Med 1996;27:153-170.
31. Xie B, Dong Z, Fidler IJ. Regulatory mechanisms for the expression of type IV collagenases/gelatinases in murine macrophages. J Immunol 1994;152:3637-3644.
32. Welgus HG, Campbell EJ, Cury JD, et al. Neutral metalloproteinases produced by human mononuclear phagocytes. J Clin Invest 1990;86:1496-1502.
33. Busiek DF, Baragi V, Nehring LC, Parks WC, Welgus HG. Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones. J Immunol 1995; 154:6484-6491.
34. Suggs SP, Thomas TD, Joy JL, Lopez-Mendez A, Oh SJ. Vasculitic neuropathy mimicking Guillain-Barré syndrome. Arthritis Rheum 1992;35:975-978.
35. Kuwabara S, Nakajima M, Matsuda S, Hattori T. Magnetic resonance imaging at the demyelinative foci in chronic inflammatory demyelinating polyneuropathy. Neurology 1997;48: 874-877.
36. Leppert D, Hauser SJ, Kishiyama JL, An S, Zeng L, Goetzl EJ. Stimulation of matrix metalloproteinase-dependent migration of T cells by eicosanoids. FASEB J 1995;9:1473-1481.
37. Rosenberg GA, Dencoff JE, Correa N, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain-barrier injury. Neurology 1996;46:1626-1632.
38. Leppert D, Waubant E, Bürk M, Oksenberg JR, Hauser SL. IFN beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-852.
39. Stüve O, Dooley NP, Uhm JH, et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863.
40. Gorson KC, Ropper AH, Clark BD, Dew RB, Simovic D, Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-α 2a. Neurology 1998;50:84-87.